A clinical trial showed that pembrolizumab, an anti-PD-1 drug, effectively improved the efficacy of paclitaxel in BC patient treatment, but not all BC patients benefited from ICI therapy [28]. This evidence concerns the gene PDCD1 and breast cancer.